Bionano Genomics (BNGO) Operating Income (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Operating Income data on file, last reported at -$7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 6.71% year-over-year to -$7.9 million; the trailing twelve-month figure through Mar 2026 stood at -$32.8 million (up 59.7% YoY), and the FY2025 full-year result was -$33.3 million, up 67.94% from the prior year.
• Operating Income rose to -$7.9 million in Q1 2026, from -$8.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$7.8 million in Q2 2025 to a low of -$113.2 million in Q3 2023.
• A 5-year average of -$29.0 million and a median of -$29.9 million in 2022 frame the typical range for Operating Income.
• Across the five-year window, Operating Income sank 252.15% in 2023 and soared 80.55% in 2025, its largest moves.
• Tracing BNGO's Operating Income over 5 years: stood at -$37.5 million in 2022, then soared by 33.51% to -$25.0 million in 2023, then jumped by 52.15% to -$11.9 million in 2024, then increased by 28.52% to -$8.5 million in 2025, then gained by 7.49% to -$7.9 million in 2026.
• Business Quant data shows BNGO's Operating Income at -$7.9 million in Q1 2026, -$8.5 million in Q4 2025, and -$8.5 million in Q3 2025.